How much profit has Cyclopharm made this year?
Cyclopharm has made -1.8 M AUD this year.
Cyclopharm Net Income 2025
Cyclopharm Net Income
-1.8 M AUD
Ticker
CYC.AX
ISIN
AU000000CYC5
In 2025, Cyclopharm's profit amounted to -1.8 M AUD, a -84.91% increase from the -11.9 M AUD profit recorded in the previous year.
The Cyclopharm Net Income history
| YEAR | NET INCOME (undefined AUD) |
|---|---|
| 2027e | - |
| 2026e | 11.23 |
| 2025e | -1.8 |
| 2024e | -11.9 |
| 2023 | -4.7 |
| 2022 | -6.61 |
| 2021 | -5.04 |
| 2020 | -6.04 |
| 2019 | -2.91 |
| 2018 | -0.04 |
| 2017 | -1.52 |
| 2016 | 0.89 |
| 2015 | 4.79 |
| 2014 | 4.07 |
| 2013 | -9.64 |
| 2012 | -1.04 |
| 2011 | -0.96 |
| 2010 | 0.45 |
| 2009 | 2.04 |
| 2008 | 1.76 |
| 2007 | 1.13 |
| 2006 | 2.03 |
| 2005 | 1.58 |
Cyclopharm Revenue, EBIT, Net Income AU000000CYC5 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Cyclopharm, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cyclopharm from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cyclopharm’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Cyclopharm. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Cyclopharm’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Cyclopharm’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cyclopharm’s growth potential.
Cyclopharm Revenue, EBIT and net profit per share
| Date | Cyclopharm Revenue | Cyclopharm EBIT | Cyclopharm Net Income |
|---|---|---|---|
| 2027e | 78.91 M undefined | 0 undefined | 0 undefined |
| 2026e | 67.97 M undefined | 14.44 M undefined | 11.23 M undefined |
| 2025e | 46.97 M undefined | -101,000 undefined | -1.8 M undefined |
| 2024e | 28.28 M undefined | -10.54 M undefined | -11.9 M undefined |
| 2023 | 27.77 M undefined | -8.6 M undefined | -4.7 M undefined |
| 2022 | 24.96 M undefined | -5.89 M undefined | -6.61 M undefined |
| 2021 | 17.85 M undefined | -4.52 M undefined | -5.04 M undefined |
| 2020 | 14.68 M undefined | -5.48 M undefined | -6.04 M undefined |
| 2019 | 14.1 M undefined | -3.31 M undefined | -2.91 M undefined |
| 2018 | 13.51 M undefined | -169,390 undefined | -35,460 undefined |
| 2017 | 13.27 M undefined | 725,220 undefined | -1.52 M undefined |
| 2016 | 14.43 M undefined | 1.44 M undefined | 891,370 undefined |
| 2015 | 12.63 M undefined | 2.01 M undefined | 4.79 M undefined |
| 2014 | 12.07 M undefined | 630,000 undefined | 4.07 M undefined |
| 2013 | 11.9 M undefined | -410,000 undefined | -9.64 M undefined |
| 2012 | 10.77 M undefined | -430,000 undefined | -1.04 M undefined |
| 2011 | 10.33 M undefined | -50,000 undefined | -960,000 undefined |
| 2010 | 9.53 M undefined | 1.59 M undefined | 450,000 undefined |
| 2009 | 13.6 M undefined | 2.7 M undefined | 2.04 M undefined |
| 2008 | 10.94 M undefined | 2.15 M undefined | 1.76 M undefined |
| 2007 | 11.23 M undefined | 1.61 M undefined | 1.13 M undefined |
| 2006 | 10.34 M undefined | 2.63 M undefined | 2.03 M undefined |
| 2005 | 9.13 M undefined | 2.72 M undefined | 1.58 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2005 | 9.13 M AUD | 2.72 M AUD | 1.58 M AUD |
| 2006 | 10.34 M AUD | 2.63 M AUD | 2.03 M AUD |
| 2007 | 11.23 M AUD | 1.61 M AUD | 1.13 M AUD |
| 2008 | 10.94 M AUD | 2.15 M AUD | 1.76 M AUD |
| 2009 | 13.6 M AUD | 2.7 M AUD | 2.04 M AUD |
| 2010 | 9.53 M AUD | 1.59 M AUD | 450,000 AUD |
| 2011 | 10.33 M AUD | -50,000 AUD | -960,000 AUD |
| 2012 | 10.77 M AUD | -430,000 AUD | -1.04 M AUD |
| 2013 | 11.9 M AUD | -410,000 AUD | -9.64 M AUD |
| 2014 | 12.07 M AUD | 630,000 AUD | 4.07 M AUD |
| 2015 | 12.63 M AUD | 2.01 M AUD | 4.79 M AUD |
| 2016 | 14.43 M AUD | 1.44 M AUD | 891,370 AUD |
| 2017 | 13.27 M AUD | 725,220 AUD | -1.52 M AUD |
| 2018 | 13.51 M AUD | -169,390 AUD | -35,460 AUD |
| 2019 | 14.1 M AUD | -3.31 M AUD | -2.91 M AUD |
| 2020 | 14.68 M AUD | -5.48 M AUD | -6.04 M AUD |
| 2021 | 17.85 M AUD | -4.52 M AUD | -5.04 M AUD |
| 2022 | 24.96 M AUD | -5.89 M AUD | -6.61 M AUD |
| 2023 | 27.77 M AUD | -8.6 M AUD | -4.7 M AUD |
| 2024e | 28.28 M AUD | -10.54 M AUD | -11.9 M AUD |
| 2025e | 46.97 M AUD | -101,000 AUD | -1.8 M AUD |
| 2026e | 67.97 M AUD | 14.44 M AUD | 11.23 M AUD |
| 2027e | 78.91 M AUD | 0 AUD | 0 AUD |
Cyclopharm stock margins AU000000CYC5 ·
The Cyclopharm margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cyclopharm. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cyclopharm.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Cyclopharm's sales revenue. A higher gross margin percentage indicates that the Cyclopharm retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Cyclopharm's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Cyclopharm's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cyclopharm's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cyclopharm. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cyclopharm's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Cyclopharm Margin History
| Cyclopharm Gross margin | Cyclopharm Profit margin | Cyclopharm EBIT margin | Cyclopharm Profit margin |
|---|---|---|---|
| 2027e | 63.06 % | 0 % | 0 % |
| 2026e | 63.06 % | 21.25 % | 16.51 % |
| 2025e | 63.06 % | -0.22 % | -3.82 % |
| 2024e | 63.06 % | -37.26 % | -42.07 % |
| 2023 | 63.06 % | -30.97 % | -16.93 % |
| 2022 | 70.2 % | -23.59 % | -26.48 % |
| 2021 | 71.75 % | -25.3 % | -28.24 % |
| 2020 | 73 % | -37.31 % | -41.17 % |
| 2019 | 79.38 % | -23.43 % | -20.65 % |
| 2018 | 78.05 % | -1.25 % | -0.26 % |
| 2017 | 80.05 % | 5.47 % | -11.49 % |
| 2016 | 75.62 % | 9.97 % | 6.18 % |
| 2015 | 78.84 % | 15.92 % | 37.95 % |
| 2014 | 71.58 % | 5.22 % | 33.72 % |
| 2013 | 70.5 % | -3.45 % | -81.01 % |
| 2012 | 68.9 % | -3.99 % | -9.66 % |
| 2011 | 69.7 % | -0.48 % | -9.29 % |
| 2010 | 75.76 % | 16.68 % | 4.72 % |
| 2009 | 81.25 % | 19.85 % | 15 % |
| 2008 | 76.87 % | 19.65 % | 16.09 % |
| 2007 | 72.22 % | 14.34 % | 10.06 % |
| 2006 | 73.4 % | 25.44 % | 19.63 % |
| 2005 | 77.77 % | 29.79 % | 17.31 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2005 | 77.77 % | 29.79 % | 17.31 % |
| 2006 | 73.4 % | 25.44 % | 19.63 % |
| 2007 | 72.22 % | 14.34 % | 10.06 % |
| 2008 | 76.87 % | 19.65 % | 16.09 % |
| 2009 | 81.25 % | 19.85 % | 15 % |
| 2010 | 75.76 % | 16.68 % | 4.72 % |
| 2011 | 69.7 % | -0.48 % | -9.29 % |
| 2012 | 68.9 % | -3.99 % | -9.66 % |
| 2013 | 70.5 % | -3.45 % | -81.01 % |
| 2014 | 71.58 % | 5.22 % | 33.72 % |
| 2015 | 78.84 % | 15.92 % | 37.95 % |
| 2016 | 75.62 % | 9.97 % | 6.18 % |
| 2017 | 80.05 % | 5.47 % | -11.49 % |
| 2018 | 78.05 % | -1.25 % | -0.26 % |
| 2019 | 79.38 % | -23.43 % | -20.65 % |
| 2020 | 73 % | -37.31 % | -41.17 % |
| 2021 | 71.75 % | -25.3 % | -28.24 % |
| 2022 | 70.2 % | -23.59 % | -26.48 % |
| 2023 | 63.06 % | -30.97 % | -16.93 % |
| 2024e | 63.06 % | -37.26 % | -42.07 % |
| 2025e | 63.06 % | -0.22 % | -3.82 % |
| 2026e | 63.06 % | 21.25 % | 16.51 % |
| 2027e | 63.06 % | 0 % | 0 % |
Cyclopharm Aktienanalyse
What does Cyclopharm do?
Cyclopharm Ltd is an Australian company that was founded in 1986 and has since been developing innovative medical solutions. The company operates in the field of nuclear medicine and focuses on providing diagnostic and therapeutic products and services. The history of Cyclopharm Ltd began with the development of the Technetium-99m generator, an instrument for generating radioisotopes that can be used in medical imaging. Since then, the company has expanded its offerings and now offers a wide range of products and services. Cyclopharm Ltd's business model is based on research and development of new solutions based on the needs of the medical community and patients. The company works closely with doctors, scientists, and other experts to ensure that its products and services meet the highest standards. Cyclopharm Ltd is divided into various divisions to coordinate and optimize its activities. These include diagnostics, therapy, research and development, as well as sales and marketing. Each division works closely with the others to ensure that the company achieves its goals and provides optimal customer care. Some of Cyclopharm Ltd's most well-known products include the Technetium-99m generator and the radiopharmaceutical Technegas. Technegas is a gas used for lung imaging and plays an important role in diagnosing lung problems. The radiopharmaceutical is produced using the Technetium-99m generator and is an important addition to medical imaging. In addition, Cyclopharm Ltd also develops therapeutic solutions that can be used to treat cancer and other diseases. These include radiopharmaceuticals used in radiation therapy, as well as other solutions tailored to the individual needs of patients. Cyclopharm Ltd is also actively working on improving and expanding its products and services. The company invests in research and development to develop innovative solutions that can improve medical imaging and therapy. Additionally, the company works closely with its customers to better understand their needs and offer them tailored solutions. Overall, Cyclopharm Ltd is an innovative and goal-oriented company that focuses on providing diagnostic and therapeutic solutions in the field of nuclear medicine. The company has a long history of leadership in this field and will continue to be at the forefront of developing solutions that improve the lives of patients and medical professionals. Cyclopharm ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Cyclopharm's Profit Margins
The profit margins of Cyclopharm represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Cyclopharm's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Cyclopharm's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Cyclopharm's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Cyclopharm’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Cyclopharm stock
How has the profit developed compared to last year?
The profit has increased by -84.91% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Cyclopharm publish its earnings?
Cyclopharm publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Cyclopharm?
The profits of Cyclopharm are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Cyclopharm?
You can learn more about the earnings of Cyclopharm by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Cyclopharm pay?
Over the past 12 months, Cyclopharm paid a dividend of 0.01 AUD . This corresponds to a dividend yield of about 0.47 %. For the coming 12 months, Cyclopharm is expected to pay a dividend of 0.01 AUD.
What is the dividend yield of Cyclopharm?
The current dividend yield of Cyclopharm is 0.47 %.
When does Cyclopharm pay dividends?
Cyclopharm pays a quarterly dividend. This is distributed in the months of May, October, April, October.
How secure is the dividend of Cyclopharm?
Cyclopharm paid dividends every year for the past 0 years.
What is the dividend of Cyclopharm?
For the upcoming 12 months, dividends amounting to 0.01 AUD are expected. This corresponds to a dividend yield of 0.43 %.
In which sector is Cyclopharm located?
Cyclopharm is assigned to the 'Health' sector.
Wann musste ich die Aktien von Cyclopharm kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Cyclopharm from 9/11/2023 amounting to 0.005 AUD, you needed to have the stock in your portfolio before the ex-date on 9/1/2023.
When did Cyclopharm pay the last dividend?
The last dividend was paid out on 9/11/2023.
What was the dividend of Cyclopharm in the year 2024?
In the year 2024, Cyclopharm distributed 0.01 AUD as dividends.
In which currency does Cyclopharm pay out the dividend?
The dividends of Cyclopharm are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Cyclopharm
Our stock analysis for Cyclopharm Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cyclopharm Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
